Date:12/19/2012

l Liabilities and Shareholders' Equity$
21,948$
20,772MCG DIAGNOSTICS CORPORATION AND SUBSIDIARIESConsolidated Statements of Comprehensive Income (Loss)(Unaudited in thousands, except per share amounts)Three Months Ended October 31,Year Ended October 31,2012201120122011RevenuesEquipment, supplies and accessories revenues$
7,101$
,736$
22,839$
22,912Service revenues1,1311,1574,3194,0908,2327,89327,15827,002Cost of revenuesCost of equipment, supplies and accessories revenues3,3383,10810,90210,316Cost of service revenues3593501,4451,3913,6973,45812,34711,707Gross margin4,5354,43514,81115,295Operating expenses:Selling and marketing2,4711,8288,0296,758General and administrative1,1581,0564,1464,299Research and development7918523,2463,239Amortization of intangibles1081054374204,5283,84115,85814,716Operating income (loss)7594(1,047)579Interest income21921Income (loss) from continuing operations before taxes9595(1,038)600Provision for taxes4102540Income (loss) from continuing operations5585(1,063)560Discontinued operations(Loss) income from operations of discontinued operations(31)(194)246(712)Gain on sale of discontinued operations816-816-Income (loss) from discontinued operations785(194)1,062(712)Net income (loss)790391(1)(152)Other comprehensive loss; net of taxUnrealized loss on securities-(2)(2)(5)Comprehensive income (loss)$
790$
389$
(3)$
(157)Income (loss) per share Basic  From continuing operations$
-$
.16$
(0.28)$
.15  From discontinued operations$
.20$
(0.06)$
.28$
(0.19)Total$
.20$
.10$
-$
(0.04) Diluted  From continuing operations$
-$
.15$
(0.28)$
.15  From discontinued operations$
.20$
(0.05)$
.28$
(0.19)Total$
.20$
.10$
-$
(0.04) Weighted average common shares outstandingBasic3,8853,7673,8283,767Diluted3,9293,8293,8283,842MCG DIAGNOSTICS CORPORATION AND SUBSIDIARIESConsolidated Statements of Cash Flows(In thousands)Year
'/>"/>

SOURCE MGC Diagnostics Corporation Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. QBC Diagnostics Awarded GSA Contract
2. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
3. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
4. Ariosa Diagnostics to Present and Exhibit at the 16th International Conference on Prenatal Diagnosis and Therapy
5. ZINO Society Targets Medical Devices, Healthcare IT and Diagnostics
6. Quest Diagnostics To Speak At The Wells Fargo Securities 2012 Healthcare Conference
7. Breakthrough Prostate Cancer Diagnostics
8. NicOx Signs Worldwide Licensing Agreement With Rapid Pathogen Screening, Inc. For Ophthalmic Diagnostics
9. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
10. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
11. Quest Diagnostics to Release Second Quarter 2012 Financial Results on July 19